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ABSTRACT 
This article reviews data on hepatitis G virus (HGV) prevalence 
and possible disease associations in various groups of patients, 
An important fraction of acute or chronic hepatitis cases prob- 
ably have a viral etiology and are not attributable to known 
hepatitis viruses. Therefore, researchers continually are looking 
for new hepatitis viruses. Among the agents found are mem- 
bers of GB hepatitis viruses, including GB-C virus, or HGV. 
This review presents the history of the discovery of HGV, its 
molecular biology and some methods of detection; results of 
clinical and molecular studies of HGV infection also are 
discussed. 
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About 10 to 15% of sporadic and 15 to 20% of non-A-E 
post-transfusion hepatitis cases probably have a viral eti- 
ology and are not attributable to known hepatitis viruses. 
In 1995 and 1996, two independent research groups 
described new viruses, named GBV-C and hepatitis G 
virus (HGV) respectively, that were detected in sera 
obtained from non-A-E hepatitis patients. Comparisons of 
nucleotides and amino acid sequences of the viruses 
revealed that they were isolates of the same virus. The 
name of the virus has not yet been chosen and the HGV 
nomenclature will be used throughout this article. 
The relation between the newly described virus infec- 
tion and human pathology has not yet been established. 
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There are conflicting results and more research must be 
carried out to determine whether HGV is a human 
pathogen. Numerous recent editorials, comments, and 
reviews deal with the problems of molecular characteri- 
zation, diagnosis, prevalence, and pathogenic&y of HGF7 
In this review, the published methods of HGV detection, 
as well as the results of clinical and molecular studies on 
HGV infection are described. 
DISCOVERY OF GBV-A, GBV-B, AND HGV (GBV-C) 
GB agent hepatitis originally was described by Deinhardt 
et a&lo who inoculated tamarins (Saquinus sp) with the 
serum of a surgeon with the initials “G.B.” Both the ani- 
mals inoculated directly with the GB serum and those 
inoculated with serum from tamarins with acute phase 
hepatitis, after subsequent serial passages, developed 
hepatitis. A modified version of the polymerase chain 
reaction (PCR) technique known as representational dif- 
ference analysis (RDA) was used to clone specific 
nucleotide sequences present in the infectious plasma 
from tamarins’l This led to the identification of two RNA 
viruses, GB virus A (GBV-A) and GB virus B (GBV-B), 
which possessed limited sequence identity to each other 
and to members of the hepatitis C virus (HCV) group of 
the Flaviviridae.12 Both GBV-A and GBV-B probably cause 
hepatitis in tamarins, ‘,13 but many New World monkeys 
are persistently infected with GBV-A-like viruses, and no 
signs of disease are associated with chronic infection.14 
Subsequent testing by reverse transcript PCR 
(RT-PCR) of sera from humans who possessed antibodies 
to recombinant proteins from GBV-A and GBV-B revealed 
the presence of a third, novel RNA virus, GBV-Cl5 Reverse 
transcript PCR was performed with degenerate primers 
capable of amplifying a segment of the conserved heli- 
case region from GBV-A, GBV-B, or HCV-1. 
Independent research by Linnen et al led to the iso- 
lation of a novel virus termed the hepatitis G virus 
(HGV).16 Whole RNA extracted from the serum of a 
patient with non-A-B hepatitis was reverse transcribed 
with random primers and subsequently amplified by 
sequence-independent single-primer amplification. Prod- 
ucts of amplification were cloned and a single colony of 
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an expression library, reactive with the serum of the 
patient, was identified. Multiple overlapping cDNA clones 
were generated from the colony by an anchored PCR. 
The sequences of the clones were combined to create 
HGV genome. Nucleotide and amino acid sequence analy- 
sis of HGV and GBV-C revealed that they are separate 
isolates of the same virus. Some full-length or nearly full- 
length HGV genome sequences have been determined, 
and the genome data are described according to these 
study results.16-l9 
GENOME STRUCTURE 
Flaviviruses are enveloped viruses that contain a single 
positive-sense genomic RNA molecule of about 10 kb. 
The length and the position of the structural and non- 
structural genes of the GBV-A, GBV-B, and HGV viruses are 
similar to other members of the FZaviviridae (Table 1). 
Genes predicted to encode structural (El, E2) and 
nonstructural (NS2, NS3, NS4, NSSA, NSSB) proteins are 
located at the 5’ and 3’ ends respectively.lzJ7 The genes 
coding for nonstructural proteins of the GB and HGV 
viruses appear to be similar to HCV and other members 
of the Flaviva’ridae, whereas the genes coding for struc- 
tural proteins have similarities and numerous differences. 
5’ Untranslated Regions 
The 5’ termini of the GB, HGV, and HCV virus genomes 
represent untranslated regions (UTRs). GBV-A and HGV 
contain large 5’ UTRs that have limited sequence iden- 
tity to each other but no identity with either HCV and 
GBV-B.” However, the GBV-B 5’ UTR appears similar to 
the HCV and other flaviviruses in conserved sequences 
and in closely related RNA secondary structures within 
5’ UTR.12,20 In this region of HG\! four highly conserved 
domains were found, suggesting a crucial role for the 
region in viral replication or gene expression.*l About 
90% of sequence homology within 5’ UTRs is maintained 
among the isolates from the different geographic areas.** 
Recently, Hsieh et al detected a potential hairpin structure 
also in the 5’ end of the noncoding region of HGV2* 
3’ Untranslated Region 
The 3’ ends of these viruses represent the untranslated 
regions (U’I’Rs). In general, the positive-strand RNA viruses 
conclude with a poly-(A) tract, whereas HCV concludes 
with either poly-(A) or a poly-(U) tracts.23-2j GBV-B is 
unique; it contains an additional 50 nucleotides down- 
stream from a poly-(LJ) tract.l’ The sequence of the GBV- 
A 3’ UTR possesses a sequence of 35 nucleotide; 
however, no poly-(U) or poly-(A) tracts were identtied.12 
Experiments on HGV 3’ UTR have failed to identify either 
poly-(U) or poly-(A) sequences.” In this regard, HGV 
closely resembles GBV-A. 
Table 1. Comparision of Some Genome Elements and Occurrence 
in Human of the GB Viruses and Hepatitis G and C Viruses 
Parameter GBV-A GBV-B HGV HCV 
Whole genome 
length (nt) 9653 9143 9103-9395 9401 
5’ UTR (nt) 594 445 281-551 341 
3’ UTR (nt) 198 83 313-315 72 
Polyprotein (aa) 2954 2864 2842-2933 3011 
Presence of basic 
core protein + - + 
Occurrence in 
humans - - + + 
ni = nucleoiide; aa = amino acid; UTR = untranslated regions. (Adapted from 
Simons et al7 and Linnen et aI.ls) 
GENE PRODUCTS 
GB viruses and HCV are similar in size and structure. 
Each possesses single, large, open reading frames encod- 
ing putative polyproteins of about 3000 amino acid 
residues. The structural proteins are positioned in the N- 
terminal third of the polyprotein, whereas the nonstruc- 
tural proteins are in the C-terminal two-thirds of the 
polyprotein.’ 
Structural Proteins 
GBV-B and HCV appear to encode a small (156 and 191 
amino acids, respectively), strongly basic protein (p1 11.1 
and 11.9), presumed to be the nucleocapsid or core, at 
the N-terminus of the polyprotein. Two putative enve- 
lope glycoproteins (El and E2) with several potential N- 
linked glycosylation sites are located downstream of the 
core.l* These structural proteins appear in all members 
of the Flaviviridae examined to date.z6x27 
GBV-A and HGV also encode two putative envelope 
proteins that contain relatively few potential N-linked gly- 
cosylation sites, but these viruses appear unique among 
members of the Flaviviridae in that they do not encode 
a basic core protein upstream of the viral glycoproteins.’ 
It is possible that the capsid protein is provided by an as 
yet unidentified helper virus or by a cellular protein that 
plays the role of a capsid protein5 In both of these viruses 
the initiator AUG codon is located immediately upstream 
of the putative El envelope signal sequence and may 
function as an internal ribosome entry site.28 
Nonstructural Proteins 
Amino acid sequence alignments with other members of 
the FZaviviridae suggest that the GB viral genomes 
encode supergroup II RNA helicases and supergroup II 
RNA-dependent RNA polymerases. In addition, sequence 
motifs consistent with virus-encoded proteases and pro- 
tease cleavage sites are found in each of these vit-uses,‘*J7 
predicting that every GB virus encodes five nonstructural 
proteins: NS2, NS3, NS4, NSSA, NS5B. 
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GB viruses and HCV have two proteases, one in NS2 
and a portion of NS3 that is believed to be involved in 
autocatalytic cleavage at the NS2-NS3 junction, and the 
other, a chymotrypsin-like serine protease located within 
the N-terminal one-third of NS3 that is responsible for 
processing of the downstream nonstructural proteins at 
specific recognition sites. HGV NS3-encoded serine pro- 
tease, despite low sequence homology (about 30%) shares 
substrate specificity with the HCV NS3 protease. It is 
presumed that in GB viruses such as those in HCV, host 
and viral proteases are responsible for processing of the 
structural and nonstructural proteins respectively.12x17 As 
was observed for flavi-like viruses,3o the greatest region 
of identity occurs within helicase area NS3. 
Within the putative NS5B region, a number of 
residues conserved in the supergroup II replicases of pos- 
itive-strand RNA viruses are maintained in HGV17.30 GBV- 
A and GBV-B also possess many of the conserved 
residues, however, there are some significant differences.12 
The functional role of the HCV NS4 and NSSA pro- 
teins is unknown; however, based on the regional 
sequence identity between HCV and GB viruses, these 
proteins can be expected to perform similar functions. 
HEPATITIS G VIRUS SUBTYPES 
The mutation rate of HGV is relatively low. During 8.4 
years of observation of virus isolates from one patient, 
3.9 X 10m4 base substitutions per site per year were esti- 
mated.31 Therefore, HGV appeared to be significantly less 
variable than HCV.32 Nevertheless, recent studies 
reported HGV strains with low sequence identity with 
previously reported isolates.33 They were detected 
mainly in Japanese patients, and it seemed that some 
HGV isolates should be placed in new genotypes.33 
Hepatitis G virus isolates from China were reported to 
be more similar to Japanese isolates than to isolates from 
the United States and Africa.34 In Nicaraguan patients 
the high prevalence of HGV strains related to those of 
Asian origin was detected.3j Muerhoff et al and Mukaide 
et al described three groups of HGV sequences based on 
heterogeneity within a 5’-terminal sequence.3”,37 The 
existence of two different subtypes of HGV in Italy has 
been suggested,3s the Taiwanese and Japan isolates have 
been classified into three groups,39,40 and the Mongolian 
isolates into two types.*l Okamoto et al divided HGV 
isolates into three genotypes, tentatively designated Gl , 
G2, and G3.19 These data suggest that HGV isolates 
cloned from different geographic areas have genetic het- 
erogeneity. However, Pickering et al reported only one 
level of variation within HGV sequences, in contrast to 
three distinct ranges corresponding to isolate, subtype, 
and genotype levels of variations in HCV and argued 
against these divisions in HGV.32 Smith et al discrimi- 
nated geographic variants of HGV by analysis of the 5’ 
noncoding region, and they stated that the low level of 
amino acid sequence variation observed between groups 
of variants suggested that they are unlikely to display 
significant biologic differences.42 
DETECTION OF HEPATITIS G VIRUS 
Detection of Hepatitis G  Virus RNA 
Detection of HGV genomic RNA in human serum, plasma, 
or cellular samples relies on the RT-PCR assays, which 
use oligonucleotide primers that amplify the NS3 heli- 
case domain or highly conserved regions within the 5’ 
UTR.43,44 
The NS3-based method uses degenerate oligonu- 
cleotide primers designed to the most highly conserved 
sequences of helicase domain, the amplification being 
performed by “touchdown PCR,” which allows specific 
product amplification despite small primer-template mis- 
matches that may be present.45 The detection of specific 
PCR relies on Southern hybridization.43 The second-round 
of PCR can be carried out with nested primers.46Yoshiba 
et al described the seminested PCR, using a combination 
of the sense primer and two antisense primers for ampli- 
fication of a 140-bp fragment from the conserved helicase 
region of HGV4’ 
The 5’ UTR-based method avoids the use of degen- 
erate primers as 5’ UTR possesses a high sequence con- 
servation among the isolates.44 A standard thermocycling 
protocol is used for amplification. Detection is based on 
Southern hybridization or PCR enzyme-linked immunosor- 
bent assay (ELISA) digoxygenine labelling and detection 
system (Boehringer Mannheim, Sydney).** 
Kao et al compared sensitivity and specificity of PCR 
assays using primers from different regions of the viral 
genome: 5’ UTR, E2, and NS3.49 The positive rates by 5’ 
UTR, NS3, and E2 primers were lOO%, 98%, and 84%, 
respectively, and the sensitivity of PCR assays using 5’ 
UTR primers happened to be 10 to 100 times more likely 
to detect HGV RNA than that of NS3 and E2 primers. 
Bhardwaj et al, Cantaloube et al, and Zhang et al reached 
similar conclusions.50-52 
There also are primers targeting the NSSB replicase 
region of HGV (Genelabs Technologies Inc., USA; 
Boehringer Mannheim, Germany), and such a PCR prod- 
uct is detected by dot blot hybridization using a ribo- 
probe or enzyme-linked test (Semiquantitative 
Enzymun-Test).48~53 Schlueter et al also propose the ampli- 
fication by PCR of two independent regions of the viral 
genome: 5’ UTR and NS5A.53 They demonstrated the 
increased sensitivity of HGV detection with two sets of 
primers, and this technique is applicable for routine 
screening in clinical laboratories.j3 
A manufacturer (Abbott Laboratories, Abbott Park, IL) 
has developed a single-tube assay based on RT-PCR ampli- 
fying 5’ UTR and followed by oligomer hybridization. All 
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reagents are contained in a single reaction vial, and detec- 
tion employs a microparticle enzyme immunoassay in the 
automated LCx system (Abbott Laboratories, North 
Chicago, IL).’ 
Recently, Brown and Young reported that, in their 
experience, some of the primers and probes used to 
detect HGV also give positive results in samples con- 
taining DNA of Escherichia coZi.54 
Apart from detection of HGV RNA based on RT-PCR, 
branched DNA (bDNA) signal amplification pathway 
assays have been developed; although convenient, they 
are not as sensitive as RTPCR assays.5 
Detection of Anti-Hepatitis G Virus Antibodies 
Immunoreactive regions have been identified in the puta- 
tive nonstructural proteins, particularly NS3, NS4, and 
NS5, from all three GB viruses, as well as in the putative 
core protein of GBV55,56 In the case of HGV most immuno- 
diagnostic kits use antigens derived from structural 
genes of the virus, as for example, recombinant envelope 
protein E2 expressed in the eucaryotic cell system.‘s5’ 
Antibodies to HGV E2 appeared to be directed toward 
conformational epitopes, since reactivity in ELISA was 
not detected with denatured E2 protein.58 In a study by 
Feucht et al, the antibodies most frequently found in a 
group of 709 subjects were antibodies against NS3-NS4 
recombinant protein, followed by the NS3 protein and 
core protein.56 
PHYLOGENETIC ANALYSIS 
The evolutionary relation between the GB viruses and 
other members of the Flaviviridae has been assessed by 
comparison of nonstructural genes coding RNA helicases 
and RNA-dependent RNA polymerases. 
Within the GB virus family, GBV-A and HGV are more 
closely related (48% amino acid sequence identity), but 
they appear unique, with respect to other members of 
the Flaviviridae, in that they do not encode a basic core 
protein, as do GBV-B and HCV’ However, GBV-B bears 
no more resemblance to HCV than it does to the other 
GB viruses. It seems that, on the phylogenic tree, the 
HCV genotypes are tightly grouped on a major branch, 
GBV-B stands alone on a second major branch, whereas 
HGV and GBV-A are present on a third major branch, 
though these viruses further diverge from a common 
ancestor.” Sequence comparison of HGV isolates from 
different geographic areas indicates that Chinese and 
Japanese HGV strains may have a closely related ances- 
try that probably is different from that of American and 
African strains.34 
Recently Viazov et al tested 39 blood samples HGV- 
RNA positive from different parts of the world and 
reported that on a phylogenic tree all HGV sequences of 
isolates from Africa, south and southeast Asia were clus- 
tered together and were separated from those collected 
in Europe, North America, and central Asia.59 
ROUTES OF HEPATITIS G VIRUS TRANSMISSION 
Hepatitis G virus is transmitted mainly through blood and 
blood products. 6o-62 In some studies, the median level of 
serum HGV viremia was found to be about 10 times 
higher than that of HCV in chronically infected subjects; 
therefore, the risk of transmission through blood prod- 
ucts, sexual contact, or from mother to infant might be 
higher for HGV than for HCV63 The positivity of HGV 
RNA is about twice as frequent in patients with non-A-E 
hepatitis following blood transfusion than in sporadic 
non-A-E hepatitis cases.* The high frequency of infection 
is present in all groups of patients repeatedly exposed 
to blood products.* Among bone marrow transplant 
recipients who had received transfusions of intravenous 
immunoglobulin and cellular components, the propor- 
tion of HGV-infected subjects was higher than among 
patients with common variable immune deficiency who 
had received only intravenous immunoglobulin6* In 
consequence this mode of HGV transmission also occurs 
during transplantation,65,6h and with the use of blood- 
contaminated instruments in intravenous drug addiction. 
In patients on maintenance hemodialysis, new HGV infec- 
tions occur without blood transfusions; therefore, HGV 
may be a marker of nosocomial viral transmission.67 
Sequences of HGV in commercial blood donors or in 
hemodialysis patients are similar, suggesting spread among 
restricted groups and nosocomial infection.34,68 Among 
professional blood donors, plasmapheresis was identified 
as a significant risk factor of HGV infection.69 
Reports indicated that infectiousness of HGV through 
blood products was low or the clearance of the virus 
was rapid. ‘O Hepatitis G virus RNA was detected in 7 to 
40% of commercial plasma pools used for the produc- 
tion of blood products’l A high frequency of HGV-RNA 
contamination (about 100%) in batches of immunoglob- 
ulins manufactured without specific viral inactivation pro- 
cedures has been reported.72,73 Garcia-Trevijano et al 
found HGV RNA in 14% of 14 different commercial coag- 
ulation-factor concentrates.‘* Despite the prevalence, 
none,73,75 or only 12.5 to 14% of recipients of such prod- 
ucts were positive for HGV at the time of testing during 
follow-up. ‘O,” In immunocompromised patients, the rate 
of HGV persistence following blood-borne infection may 
be higher. One study reported that 7 of 17 (41%) initially 
HGV-RNA-negative patients who underwent liver trans- 
plantation had persistent HGV viremia during follow-up 
of between 5 months and 4 years.‘” 
The possibility of sexual HGV transmission is highly 
probable but not clear at the moment.77z78 Persico et al 
detected HGV RNA in 25 to 50% of samples of seminal 
plasma obtained from serum HGV-RNA-positive 
patients. 79,80 The prevalence of HGV RNA was signifi- 
cantly higher in heterosexual partners of HGV-RNA-pos- 
itive subjects than in those who were HGV-RNA 
negative.81 The frequency of infection also was higher in 
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the group of prostitutes and homosexual men compared 
with the partners of HGV-RNA-negative subjects.81~82 
There is a high prevalence of HGV infection among non- 
intravenous drug-using homosexual and bisexual men.83 
Mother-to-child transmissions of HGV have been 
shown in several cases.61~84~s5 Among 12 babies born to 
HGV-RNA-positive mothers, 3 (25%) were HGV-RNA pos- 
itive at birth.86 Feucht showed vertical HGV transmission 
to three of nine (33.3%) babies born to HGV-positive 
mothers.*’ The rate of HGV mother-to-infant transmission 
is higher compared with human immunodeficiency virus 
type 1 (HIV-l) or HCV The mode of delivery (e.g., elec- 
tive caesarean delivery) may influence the transmission 
of HGVs8 Moaven et al described the case of a breastfed 
baby born to an HGV-RNA-positive mother. The baby was 
HGV-RNA negative at birth, but tested HGV-RNA positive 
at both 4 and 6 weeks of age, without any signs of liver 
disease.48 
Hepatitis G virus RNA was detected in saliva of 33% 
(2/6) of infected subjects. 89 Thus, it is possible that HGV, 
like other flaviviruses, can be spread horizontally or be 
transmitted by mosquitoes.90~91 
PREVALENCE OF HEPATITIS G VIRUS INFECTION 
The reported prevalence of HGV infection in selected 
groups of subjects in some published studies is listed in 
Table 2. Only some groups of patients were selected for 
presentation. The frequency of positivity for HGV RNA or 
anti-HGV antibodies varies among groups, and depending 
on the subjects’ origins and the method used for HGV 
infection marker detection. Generally, infection with HGV 
is significantly associated with a history of intravenous 
drug use, with exposure to transfusions of blood products 
or dialysis, and with HCV infection, especially with HCV 
genotype 3a.63 
Table 2. Reported Prevalence of HGV Infection in 
Selected Groups of Subjects in Some Published Studies 
Prevalence of HGV 
Infection Markers 
Number of Cases 
in Selected Group HGV RNA (%) HGVAb (%) 
Blood donors, mainly voluntary healthy adults 
1478 1.6 
1048 1.3 
500 4.2 
500 1.4 
448 0.9 
358 1.1 
257 1.9 
257 Not reported 15.9 
205 1.0 
200 3.0 
200 0.5 
186 1.1 5.4 
165 1.2 
Reference 
Number 
16 
61 
64 
99 
68 
144 
161 
56 
34 
162 
163 
164 
142 
Table 2. continued 
Prevalence of HGV 
Infection Markers 
Number of Cases Reference 
in Selected Group HGV RNA (77) HGV Ab (%j Number 
150 0.7 
145 1.4 
129 0.8 
125 3.2 
121 6.6 
120 4.2 
100 1 .o 
100 1.0 
90 2.2 
81 7.4 
80 2.5 
69 4.3 
60 1.7 
59 3.4 
50 2.0 
30 Not reported 
Acute non-A-E hepatitis patients 
54 7.4 
48 2.1 
45 8.9 
38 13.2 
37 10.8 
31 35.5 
28 3.6 
Fulminant non-A-E hepatitis patients 
25 12.0 
16 37.5 
16 12.5 
13 0.0 
11 0.0 
10 50.0 
9 0.0 
7 42.9 
7 0.0 
6 50.0 
Chronic non-A-E hepatitis patients 
158 9.5 
76 5.3 
67 14.9 
34 5.9 
20 10.0 
18 38.9 
14 64.3 
69 
165 
166 
72 
41 
167 
38 
116 
83 
168 
9.0 97 
169 
3.3 57 
170 
171 
3.3 172 
165 
166 
96 
16 
173 
38 
118 
106 
105 
174 
116 
123 
103 
107 
173 
175 
47 
16 
142 
110 
166 
116 
38 
14.3 57 
Post-transfusion non-A-E hepatitis patients 
15 26.7 
13 23.1 
13 (non-A-C) 23.1 
8 12.5 
Non-A-E hepatitis patients 
154 1.9 
149 8.7 
126 1.6 
76 13.2 
49 36.7 
12 Not reported 25.0 
HBV-infected patients 
220 
102 
100 
83 
72 
58 
38 
33 
23 
19 
3.2 
6.9 
32.0 
3.6 
9.7 
10.3 
5.3 
21.2 
4.3 
5.3 
101 
16 
99 
98 
161 
173 
52 
17 
38 
173 
116 
166 
96 
108 
16 
66 
52 
176 
163 
110 
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Table 2. continued Table 2. continued 
Prevalence of HGV Prevalence of HGV 
Infection Markers Infection Markers 
Number of Cases Reference Number of Cases Reference 
in Selected Group HGV RNA (‘%) HGVAb 1%) Number in Selected Group HGV RNA (%) HGVAb (%) Number 
HCV-infected patients 
361 
228 
207 
189 
188 
179 
159 
143 
128 
126 
7.4 
21.1 
8.2 
11.1 
8.0 
12.3 
25.3 
5.6 
7.0 
5.6 
177 
63 
52 
114 
108 
166 
178 
154 
179 
163 
119 24.4 161 
117 23.9 113 
116 19.8 96 
115 15.6 115 
107 17.8 16 
105 16.2 112 
100 
100 
91 
83 
74 
74 
70 
63 
62 
62 
53 
51 
19.0 
10.0 
16.6 
26.5 
16.2 
8.1 
25.7 
9.5 
16.1 
16.1 
20.7 
25.5 
40 27.5 
39 20.5 
34 17.6 
30 23.3 
25 8.0 
22 40.9 
Autoimmune hepatitis patients 
60 0.0 
53 9.4 
Cryptogenic cirrhosis patients 
45 22.2 
10 0.0 
Hepatocellular carcinoma patients 
213 5.6 
139 12.2 
60 6.0 
50 16.0 
39 2.6 
36 11.1 
30 6.7 
30 10.0 
37.3 
180 
116 
110 
181 
152 
66 
182 
99 
183 
50 
122 
56 
184 
125 
89 
77 
176 
118 
185 
16 
186 
166 
187 
165 
166 
188 
189 
108 
16 
116 
29 6.9 163 
20 40.0 171 
16 18.7 117 
Hemophiliacs 
95 13.7 72 
81 9.9 119 
63 23.8 190 
49 18.4 16 
45 20.0 48.9 172 
45 37.8 35 
37 2.7 191 
17 35.2 52.9 161 
IO 30.0 116 
Hepatitis-associated aplastic anemia patients who did not receive 
transfusion 
4 50.0 133 
Idiopathic aplastic anemia patients who did not receive transfusion 
19 21 .o 
Aplastic anemia patients HAV-HCV negative 
10 30.0 
B-cell non-Hodgkin lymphoma patients (untreated) 
150 6.0 
51 2.0 
Patients on hemodialysis 
519 
172 
119 
100 
96 
79 
78 
69 
65 
61 
59 
59 
58 
20 
Prostitutes 
193 
145 
140 
3.5 
6.4 
16.0 
19.0 
26.0 
54.4 
34.6 
10.1 
15.4 
57.5 
6.8 
Not reported 
55.2 
15.0 
13.9 81 
11.0 78 
21.4 a2 
Homosexual men 
149 13.4 81 
Intravenous drug users 
246 15.4 
130 33.1 
130 33.1 
117 35.0 
99 38.3 
95 15.8 
90 28.9 
85 75.3 
70 25.7 
60 33.3 
59 28.8 
59 Not reported 
57 31.6 
52 13.5 
49 24.5 
43 48.8 
40 32.5 
27 3.7 
13 15.4 
40 15.0 
HIV-infected patients 
100 9.0 
55 18.2 
55 Not reported 
Cadaver organ donors 
158 17.1 
25.4 
41.4 
47.5 
40.4 
72.5 
85.2 
29.1 
Organ or bone marrow transplant recipients 
243 (heart) 23.9 
221 (kidney) 14.0 39.8 
109 (liver) 44.9 
94 (kidney) 42.6 
a9 (marrow) 24.7 
87 (kidney) 27.5 
59 (marrow) 42.3 
44 (liver) 63.6 
39 (liver) 43.6 
33 (marrow) 60.6 
133 
131 
142 
140 
68 
192 
67 
193 
162 
34 
170 
166 
194 
195 
161 
56 
189 
196 
197 
53 
83 
198 
97 
173 
79 
171 
182 
16 
161 
56 
63 
172 
179 
199 
57 
164 
17 
116 
71 
161 
56 
65 
151 
200 
123 
169 
64 
201 
202 
124 
111 
203 
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Table 2. continued 
Prevalence of HGV 
infection Markers 
Number of Cases Reference 
in Selected Group HGV RNA (%) HGVAb (%) Number 
25 (liver) 64.0 188 
11 (kidney) 54.5 150 
11 (kidney) 36.4 192 
Only some groups of patients were selected for presentation. Positivity of HGV 
RNA determined by RT-PCR. Positivity of anti-HGV-protein antibodies (HGV Ab) 
determined by ELBA. 
HEPATITIS G VIRUS AS A 
HEPATITIS ETIOLOGIC AGENT 
The significance of HGV infection as a cause of various 
hepatitis forms is controversial to date, and it is not 
known if HGV is a true “hepatitis”~irus.~~m9* Patients with 
aminotransferase elevation of unknown etiology have a 
low prevalence (13%) of HGV infection and liver histol- 
ogy that is indistinguishable from that of patients with- 
out HGV infection.95 The reported prevalence of HGV 
infection in cases of acute sporadic hepatitis varies in 
published studies (see Table 2), but it is low, and HGV 
seems not to be a serious etiologic agent of acute non- 
A-E hepatitis.94 In the course of acute HGV infection, if 
there is any elevation of aminotransferase levels, it almost 
always is moderate; therefore, the infection often is un- 
detectable by both patients and physicians. In a study of 
well-defined community-acquired disease, only 4 of 45 
non-A-E hepatitis patients were HGV positive and three 
of these patients had jaundice, in contrast to the major- 
ity of cases of HGV infection.9G Contrary to the data, 35% 
of Italian non-A-E acute hepatitis subjects were positive 
for the HGV genome.38 In some cases, HGV appearance 
or clearance (detected with PCR) was accompanied, 
respectively, by the elevation or sharp decrease in serum 
transaminase concentration.62x97 
Hepatitis G virus RNA is detectable in about 20% of 
post-transfusion non-A-E hepatitis cases (see Table 2). The 
disease often is mild, and elevated serum transaminase 
concentrations are found in only a small percentage of 
cases.98-101 In acute post-transfusion hepatitis with HGV 
infection alone, serum alanine transaminases were ele- 
vated for 2 to 8 weeks and resolved 5 months after trans- 
fusion.lOO~lO’ The course of infection was studied in some 
cases, and was accompanied by virus clearance in the 
majority of immunocompetent patients.99,100 In some 
patients, however, both HGV RNA and elevated amino- 
transferase levels persisted over a longer period.99,102 The 
clinical pictures of acute infection with HCV alone or 
HCV-HGV co-infection are similar.1oo 
In some countries, HGV infection often is found in 
patients with fulminant non-A-E hepatitis (see Table 2). 
The significance of this is controversial, as almost no 
cases of fulminant hepatitis were induced by transfusion 
of blood products negative for HBV or HCV infection 
markers.“* However, it could not be excluded that a small, 
but significant percentage of fulminant hepatitis cases 
may be attributable to HGV infection, especially in asso- 
ciation with other hepatitis viruses,1o3 but also alone.103-106 
In addition, Heringlake et al reported a specific strain of 
HGV associated with non-A-E fulminant hepatitis in Ger- 
man patientslo andYoshiba et al showed that therapeutic 
transfusion-mediated transmission of HGV after the onset 
of fulminant hepatitis had only a minor role in overall 
HGV-RNA positivity.105 However, it also was shown that 
HGV is not usually present in cases with fulminant hepati- 
tis on initial diagnosis. lo7 As proposed by Sugai et al, most 
HGV strains may induce mild or subclinical liver disease, 
although some HGV variants might have high disease- 
inducing activity, caused, for example, by active replica- 
tion mutations. lo8 
A high percentage of HGV-RNA-positive non-A-E 
hepatitis in Italian patients was reported.38 The authors 
assumed that the prevalence should be similar to that in 
other published studies, but the detection method 
strongly influenced results. In addition, they wrote that 
it could not be excluded that apparently HGV-negative 
patients had actually been infected with HGV variants 
that escaped detection. 
In the majority of published studies, HGV infection 
has not been associated with serious chronic liver dis- 
ease.94 In a minor number of clinical studies, the associ- 
ation between HGV infection and greater activity of liver 
enzymes was reported, but only some of the subjects 
tested had levels considerably higher than normal.13z109 
Colombatto et al reported the association between ele- 
vation of cholestatic enzymes and nonspecific inflam- 
matory bile duct lesions with HGV infection.l” They 
assumed that a lesion of the bile duct leading to such 
elevation might be specific for HGV, and suggested that 
HGV detection should be a routine diagnostic element of 
cholestatic syndromes of unknown etiology.“l In many 
observations, there was no correlation between HGV 
infection and elevation of cholestatic enzymes. Although 
co-infection with HGV does not influence the clinical 
course or histopathologic picture of chronic HBV or HCV 
infection in most cases,63,98,112-117 in some, HGV seems to 
interfere with HCV and helps eliminate it: the HCV 
viremia in HGV co-infected patients was about twofold 
lower than in patients with HCV infection alone.99~11s,119 
Hepatitis G virus is not likely to be the cause of the major- 
ity of cases of cryptogenic cirrhosis,12o but in about 10% 
of such cases HGV infection was the only identifiable 
cause of chronic disease.121 Japanese leprous patients 
infected with HGV alone did not have elevated serum 
aminotransferase levels.46 Sugai et al detected HGV more 
frequently in patients with liver cirrhosis than in those 
with chronic hepatitis, and they suspected the possible 
role of HGV in aggravating liver disease.lo8 
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During liver transplantation, pretransplant HGV 
viremia has been reported to be associated with post- 
transplant viremia in 50 to 80 or 100% of cases.111~‘22J23 
In the absence of HBV or HCV infection in liver transplant 
recipients, the prevalence of HGV infection has no influ- 
ence on the graftlll Co-infection with HGV-HBV or HGV- 
HCV does not increase the frequency of occurrence of 
post-transplant graft hepatitis and overall clinical profile 
of patients. 66~111~124~125 Moreover, a significant tendency 
toward a lower number of cases of graft hepatitis in HGV- 
HCV co-infected patients compared with patients with 
HCV infection alone has been reported.66 However, 
Murthy et al observed a higher risk of post-transplanta- 
tion liver disease among the recipients of renal transplant 
with pretransplantation HGV infection.tz6 
The prevalence of HGV RNA in patients with autoim- 
mune hepatitis does not differ significantly from that in 
blood donors.l” One case has been described of long- 
term liver dysfunction with liver enzyme elevation after 
bone marrow transplantation in which HGV was the only 
known hepatitis virus isolated.lo2 
In two series, babies who were HGV-RNA positive at 
birth or later, showed no signs of liver disease over a fol- 
low-up of about 1 year.86~87 
Results obtained by Kudo et al probably explain the 
small contribution of HGV infection to the severity and 
progression of liver disease in HCV-co-infected subjects.128 
In liver samples, the estimated amount of HCV RNA was 
about 10,000 times more than HGV RNA; nevertheless, 
the serum amounts were similar.128 Therefore, the rates 
of viral replication in liver tissue must differ strongly, and 
in addition, HGV seems to replicate in other tissues. 
La&us et al similarly reported absence of detectable HGV 
replication in liver tissue samples obtained from both 
HGV- and HCV-infected patients with similar serum lev- 
els of the RNA of the viruses.‘29 
HEPATITIS G VIRUS INFECTION 
AND OTHER DISEASES 
The possible role of HGV infection in the pathogenesis 
of some rare non-liver diseases has been suggested, but 
it is too early to say that HGV is an etiologic agent of 
these. However, currently, the role of HGV cannot be 
excluded. 
Aplastic anemia is sometimes preceded by hepatitis, 
frequently of unknown origin. Hepatitis A, B, and C viruses 
have been excluded as the responsible agents.130,131 In 
some cases of hepatitis-associated aplastic anemia, HGV 
was the only infectious agent detected, even if the 
patients had not received any transfusion before diagno- 
sis.130-134 Moriyama et al detected HGV RNA in only 5 of 
18 patients with aplastic anemia who had received blood 
transfusions before testing, but in none of eight patients 
who had not received transfusions.135 The data were con- 
sistent with those reported by Brown et al, who found 
HGV RNA in 26.3% of patients with aplastic anemia and 
in 23.1% of multiply transfused control patients (differ- 
ence not statistically significant).136 In contrast to these 
data, Kiem et al detected HGV RNA in 26.1% of 23 serum 
samples obtained from both subjects with hepatitis-asso- 
ciated aplastic anemia and those with idiopathic aplastic 
anemia who did not receive transfusions.13* They con- 
cluded that although transfusions are a major source of 
HGV infection in serum of patients with aplastic anemia, 
the increased prevalence of HGV RNA in subjects not 
transfused suggests involvement of HGV in the develop- 
ment of aplastic anemia, whether associated with hepati- 
tis or not.13* 
In some studies the prevalence of HGV infection was 
significantly higher in patients with hepatocellular car- 
cinoma @ICC) compared with the healthy population or 
patients with chronic hepatitis. 108,116,137,138 Therefore, HGV 
could be a risk factor for HCC.13’ Berg et al reported a 
significantly higher prevalence of HCC in patients with 
HGV and HCV co-infection compared with patients with 
HCV infection alone,” and they speculated that HGV co- 
infection in chronic HCV-infected patients may be a cofac- 
tor in the development of HCC. 
The HGV like HCV; infection was suspected to be 
one of the factors initiating non-Hodgkin lymphomas or 
mixed cryoglobulinemia. In contrast to HCV infection, 
however, data on prevalence of HGV infection in lym- 
phoma or cryoglobulinemia patients do not support the 
hypothesis that this virus also may play a major role in 
lymphomagenesis. or in the production of mixed cryo- 
globulinemia. 139-141 Nevertheless, HGV prevalence in Ital- 
ian patients with B-cell non-Hodgkin lymphoma was 
significantly higher than in healthy subjects,142 and HGV 
infection should be studied to clarify all other clinical 
implications of this infection. 
The data presented, taken together, show that HGV 
is not a classic hepatitis virus, and it may cause liver dam- 
age in only a small percentage of infected persons. These 
results are consistent with rare findings that HGV may be 
primarily a lymphotropic agent, like Epstein-Barr virus, 
and may cause hepatitis only under special circum- 
stances.13s’43 Hepatitis G virus RNA also may be detected 
in peripheral mononuclear blood cells (PBMC) of serum 
in HGV-negative patients. ‘** However, in Flaviviridae, 
the presence of antigenomic (minus) RNA strand is con- 
sidered to be evidence of viral replication, Madejon et al 
found the genomic strands of HGV RNA in serum, liver, 
and peripheral blood cell samples obtained from patients 
with chronic hepatitis B, C, or D, but antigenomic strands 
were found only in liver samples.145 Saito et al detected 
plus-stranded HGV RNA in serum and liver samples 
obtained from six patients with hepatitis and in PBMC 
samples from five of the patients, but minus-stranded in 
only six liver, two serum, and one PBMC sample.146 Gen- 
erally, the HGV-RNA-negative strand is only rarely detected 
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in PBMC; it has not been established whether HGV 
actively replicates there, l*’ nor is it known whether it 
replicates in lymph nodes. The replication of HGV is also 
possible in human cultured-cell lines, both those derived 
from a human T-cell leukemia virus infected T-cell line 
and a non-neoplastic human hepatocyte line.148 
HUMAN IMMUNE SYSTEM AND 
HEPATITIS G VIRUS INFECTION 
Anti-EL? antibodies to HGV can be detected by commer- 
cially available tests. E2 is an HGV surface protein, and this 
antigen has been presumed to be a target for host 
humoral immune response.55z56s97 The seroconversion to 
anti-E2 antibodies is often associated with loss of 
detectable HGV viremia,l’ and detection of anti-E2 anti- 
bodies may be useful for diagnosing recovery from HGV 
infection. However, it is not known how many years anti- 
E2 positivity remains. In addition, some patients became 
HGV-RNA negative without developing an anti-E2 immu- 
nity.97 Nevertheless, the E2 antibodies seem to be a tool 
of effective response. Similarly, only the minority of sub- 
jects with either HGV-RNA or anti-HGV recombinant pro- 
tein (NS3-NS4, NS3, or core) antibody positivity showed 
HGV nucleic acids and antibody response in parallel.56 
Because of the lack of hypervariable regions in HGV 
genome, the virus would use a strategy for persistence 
other than immune escape.31 
In a number of studies, a higher occurrence of chronic 
HGV infection was reported in immunosuppressed patients 
compared with immunocompetent subjects,64~149,150 but, 
for example, Wolff et al did not find any relation between 
immunosuppression and HGV infection.151 
Once acquired, HGV infection may persist for many 
years in infected subjects, but not all the possibilities of 
HGV resistance currently are known. 
HEPATITIS G VIRUS AND ANTIVIRAL AGENTS 
There are conflicting opinions concerning the sensitivity 
of HGV to antiviral therapy: in some studies it seemed to 
be similar to HCV114,115 but independent15$ however, the 
response may be different.153,154 
During interferon-o (IFN-a) therapy, the serum HGV- 
RNA level decreases in most patients treated, and it may 
become undetectable.63,114,115.15z~154~155 Peripheral mono- 
nuclear blood cell HGV RNA was preferentially sensitive 
to interferon treatment and usually became undetectable 
shortly after the initiation of the treatment, despite the 
possibility of sustained presence of HGV RNA in serum 
or plasma. I** In only a small percentage of these patients 
the response was sustained and after the discontinuation 
of treatment HGV viremia returned in most or all sub- 
jects. 13,63,114,115,154,156,1j7 The sustained response was more 
probable in patients with a low pretreatment virus 
lOad 152,154 
In the cases of HGV-HCV co-infection Tong et al 
found that HGV infection was more common in patients 
with chronic HCV infection that did not respond to IFN- 
(Y compared with those who did,15’ but this was an iso- 
lated finding. Contrary to their opinion, most researches 
detect no influence of HGV infection in response to IFN- 
01 in patients with chronic hepatitis C.63s114*154 
Ribavirin has no potent anti-viral activity against 
HGv158,1%’ 
CONCLUSIONS 
The sensitivity of the HGV-detection methods still has 
not been established in detail. Recent results have shown 
that the virus is globally distributed, parenterally trans- 
missible, and can induce persistent viremia in humans. In 
the majority of reported studies, HGV seems to be an 
“accidental tourist,“94,160 but some findings suggest that, 
in some cases, it may be a serious pathogenic agent. Fur- 
ther studies are necessary to obtain sufficient data on the 
role of HGV in human pathology. 
NOTE 
Since this article was accepted for publication, numer- 
ous additional studies on HGV have been reported, but 
the general opinion of its low or only conditional patho- 
genicity and worldwide prevalence has not changed.Z04,205 
A new pathogen, namely, transfusion-transmitted virus 
(TIV) has become a new focus of viral hepatitis research. 
This is a DNA nonenveloped virus with numerous simi- 
larities to HGV worldwide distribution,206,207 low disease 
causative capability,Z08~209 interferon sensitivity,210 signifi- 
cant sequence heterogeneity both in infected persons 
and in different geographic regions211,212 and presence in 
blood and other tissues, including stoo1.213 
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